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MicroRNA has been suspected to be generally involved in carcinogenesis since their first description. A first study supported this
assumption for canine mammary tumors when miRNA expression was compared to normal gland. The present study extends
these results by comparing the expression of 16 microRNA (miRNA) and 4 small nucleolar RNA (snoRNA) in tumors of different
malignancy, for example, adenomas, nonmetastasizing and metastasizing carcinomas as well as lymph node metastases, with each
other and with normal mammary gland. All neoplastic tissues differed in their miR-210 expression levels from normal gland.
While metastatic cells differed in their expression of mir-29b, miR-101, mir-125a, miR-143, and miR-145 from primary tumors,
the comparison of miRNA expression in primary tumors of different malignancy failed to reveal significant differences except for
a significant downregulation of mir-125a in metastasizing carcinomas when compared to adenomas.
1. Introduction
MicroRNA (miRNA) is an evolutionarily conserved, non-
coding, but regulatory RNA species of approximately 22
nucleotides in length. It plays a crucial role in various
physiological and pathological processes by regulating gene
expression posttranscriptionally. miRNA binds to messenger
RNA (mRNA) and thereby induces a sequence-depending
mRNA degradation or translational repression [1–3]. A
deregulation of miRNA is associated with a wide variety of
pathologic states including carcinogenesis [4]. Nevertheless,
in many cases the specific function of individual miRNA
species is still unknown. For instance, miR-10b has been
identified as a tumor suppressor which prevents human
breast cancer development but also as an oncogene which
initiates breast cancer invasion and metastasis [5]. Several
miRNA species have been identified to be involved in human
breast cancer development including miR-21, miR-145, and
miR-210 [6–8]. In veterinary medicine, only a single study is
available on miRNA expression in canine mammary tumors.
Boggs et al. [7] compared the expression levels of ten miRNA
species in malignant mammary tumors and normal canine
mammary gland and found a significant deregulation ofmiR-
21, miR-29b, let-7f, miR-15a, and miR-16 in the tumors.
In the present study, we expand these recent findings
on the impact of miRNA deregulation on canine mammary
tumors by asking for differences in expression levels of four
small nucleolar RNA (snoRNA) and 16 canine miRNA with
known relevance for human and canine mammary tumor
development in tissue samples of normal mammary gland,
adenomas, metastasizing, and nonmetastasizing canine
mammary carcinomas as well as lymph node metastases.
2. Materials and Methods
Mammary gland tissues including regional lymph nodes
from 30 dogs submitted to the Department of Veterinary
Pathology of the Freie Universita¨t Berlin were included in
the study. Clinical data of the dogs included breed, age, and
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location of tumors. All tissue samples were freshly frozen
not later than 30min after surgical excision and stored at
−80∘C until further use. Directly adjacent tissue samples
were also fixed in 4% neutral buffered formalin, routinely
processed stained with haematoxylin and eosin (HE) for
histologic examination. Ten simple mammary adenomas,
ten simple carcinomas without evidence of tumor cells in
the regional lymph node, and ten simple carcinomas with
regional lymph node metastases as well as normal mammary
gland tissues of ten dogs were selected and macrodissected
for this study to assure a tumor content of more than 80%.
The fifth sample group contained laser microdissected lymph
node metastases from five dogs with simple, metastasizing
mammary carcinoma.
The study was approved by the local animal welfare
officer. Surgical resection of the tumors was part of the
therapy according to the welfare of the animals and to the
state of the art of medical science under full anesthesia. The
study therefore had no influence on the common diagnostic
or therapeutic measures usually applied on animals with
mammary gland tumors and inclusion into the study did
not induce any additional treatments, pain, or discomfort-
inducing manipulations during the entire study.
Total RNA was extracted as previously described [9,
10]. The lymph node metastases were microdissected from
cryostat sections by laser capture microdissection as previ-
ously described [11]. All miRNA and snoRNA species were
elongated prior to cDNA synthesis by universal poly-A-
tailing and amplified by quantitative reverse transcription
PCR as previously described [9]. Housekeeping genes were
selected from the complete set of genes analyzed using
both geNorm (version 3.4) and NormFinder (version 20)
algorithms [12, 13]. The most stably expressed RNA species
were determined by calculating the gene expression stability
measure value (𝑀) using the geNorm tool as previously
described [12]. Stepwise exclusion of the least stable genes
identified miR-155, let-7f, and miR-181b as the three most
stably expressed genes. In a second approach NormFinder
analysis was performed [13] and identified miR-181b, U44,
andU48 as the threemost stable reference genes. Considering
both the results of the geNorm analysis and the NormFinder
algorithm miR-181b, miR-155, and U44 were used for data
normalization. Consequently, relative expression levels of the
miRNA and snoRNA species were determined using the
2
−ΔΔCt method [14]. Due to the different efficiencies of the
PCR assays, the actual efficiencies were used as the base of the
exponential amplification function for calculation. Statistical
significance of differences inmiRNA and snoRNA expression
levels was evaluated using the IBM SPSS Statistic 20 software.
The results in the different tissue groups were statistically
compared using the parametric ANOVA analysis. A 𝑃 ≤ 0.05
was considered statistically significant.
3. Results
Comparison of the expression levels of 16 miRNA and four
snoRNA leads to the identification of statistically different
expression levels of ninemiRNAand one snoRNA in 27 of the
400 comparisons. Of these, microdissected tumormetastases
differed most often from other tissue types. miR-101, miR-
143, and miR-145 were differently expressed in metastases
when compared to all other tissues. miR-29b differed in its
expression level between metastases and all tumor tissue
samples except normal mammary gland. miR-125a expres-
sion only differed between metastases and metastasizing
carcinomas primary sites (Table 1, Figure 1). The comparison
of the primary tumors of different malignancies identified
a difference in miR-125a expression between metastasizing
carcinoma and adenoma as the only significant difference
(Table 1, Figure 1). All other differences in expression were
restricted to comparisons between normal mammary gland
and neoplastic tissues. miR-21, miR-143, miR-194, miR-203,
miR-210, and the snoRNA U24 differed in their expression
levels between normal gland and neoplastic tissues (Table 1,
Figure 1). Of note, only miR-125a and the snoRNA U24
showed a decreased expression in the primary tumors when
compared to normal gland or adenomas while all other
significantly regulatedmiRNAhad an upregulation in benign
andmalignant primary tumors (Table 1).This was in contrast
to the observation in metastases which, except for miR-125a
and miR-210, had a general downregulation of miRNA when
compared to all other tissues (Table 1).
miR-210 was the only miRNA which allowed the dif-
ferentiation of normal mammary gland from all neoplastic
tissues. In addition, miR-210 was the only miRNA with a
continuous significant increase in expression levels between
normal mammary gland and all tumor groups and the
metastases with expression differences of 7.01-fold between
adenomas and normal gland, 10.41-fold between nonmetas-
tasizing carcinomas and normal gland, 10.72-fold between
metastasizing carcinomas and normal gland, and 19.63-fold
between metastases and normal gland (Table 1).
U24 was the only snoRNA with a significant difference in
expression. The expression difference was 0.38-fold between
themetastasizing carcinoma and the normalmammary gland
but was not significantly altered in any other comparison.
miR-9, miR-10b, miR-15a, miR-16, miR-125b, miR-136, and
let-7f as well as the snoRNA U66, Z30, and U48 had no
significant difference in expression between any of the tissues
analyzed.
4. Discussion
The aim of the present study was the identification of malig-
nancy associated miRNA expression to discover potential
malignancy marker and to further elucidate aspects of the
molecular carcinogenesis and gene expression associated
with metastatic behavior of canine mammary tumors [15].
To this end, the expression of 16 miRNA and four snoRNA
was compared between normal mammary gland, adeno-
mas, carcinomas, and metastases. Only nine of the miRNA
species and one snoRNA tested were significantly differently
expressed between the diverse tissues analyzed.
Interestingly, miR-210 was significantly overexpressed in
all neoplastic tissues when compared to normal mammary
gland. Previous work described miR-210 as a “hypoxamir”
which is upregulated in hypoxic tissues by HIF-1 action and
mediates ametabolic adaptation to anaerobic conditions [16].
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Figure 1: miRNA and snoRNA expression levels in normal gland, adenoma, nonmetastasizing carcinoma, metastasizing carcinoma, and
lymph node metastasis. Ct-values are average values of expression levels of the tissue groups normalized to three housekeeping genes.
4 ISRN Veterinary Science
The continuous upregulation of miR-210 over the course
of malignant progression may therefore be caused by an
increasing hypoxia in the developing tumor mass. miR-210
overexpression has also been associated with the formation
of capillary-like structures [17]. It can thus be hypothesized
thatmiR-210may indirectly promotemetastasis by triggering
angiogenesis in neighboring cells [18]. Another four miRNA,
miR-21, miR-143, miR-194, and miR-203, were significantly
increased in at least one mammary tumor group compared
to normalmammary gland and thereforematched the defini-
tion of an oncogenic miRNA. While this disease association
is new formiR-143 andmiR-194, a similar oncogenic function
has been suggested for miR-203 [19] in mammary cancer and
for miR-21 in several other tumors including human breast
cancer but has to be determined yet [20].
The general lack of differences in miRNA expression
between primary tumors at different stages of malignancy
was intriguing. Only miR-125a was significantly differently
expressed between metastasizing carcinoma and adenoma.
This was in contrast to the numerous miRNA differentially
expressed in metastatic tumor cells in the lymph nodes. This
difference may be caused by the different preparation of
metastatic tumor cells by laser microdissection technology
due to the otherwise high contamination of metastases tissue
samples by lymphatic cells. The macrodissected samples
of normal gland and the primary tumors in contrast also
contained, although at a minimal portion, cells of the tumor
stroma. These cells may have contributed to the recorded
downregulation of the four miRNA inmicrodissectedmetas-
tases when compared to macrodissected primary tumors and
normal mammary gland, respectively.
5. Conclusions
In conclusion, canine mammary tumors at different stages
of malignancy significantly differed from normal gland in
the expression of seven miRNA and one snoRNA species.
miRNA and snoRNA expression however failed in most
cases to discriminate primary tumors at different stages of
malignancy.
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